Table 1 Demographic and ocular characteristics of the study population

Number of subjects

10

10

–

10

10

–

Age, year

61.4 ± 3.2

64.2 ± 3.3

0.071

67.3 ± 10.3

66.3 ± 6.4

0.798

Male, %

5 (50%)

6 (60%)

0.653

3 (30%)

3 (30%)

1.000

BMI, kg/m²

26.0 ± 2.9

24.3 ± 2.5

0.194

24.2 ± 1.4

26.3 ± 4.2

0.152

SBP, mm Hg

143.4 ± 15.0

139.4 ± 22.5

0.646

135.9 ± 10.9

139.1 ± 19.4

0.654

DBP, mm Hg

73.2 ± 5.6

79.3 ± 13.9

0.214

72.9 ± 8.0

70.1 ± 9.5

0.486

HbA1c, %

7.4 ± 1.5

6.8 ± 1.5

0.415

6.4 ± 0.7

6.9 ± 0.3

0.125

TG, mmol/L

2.2 ± 1.0

2.7 ± 2.2

0.476

2.1 ± 1.1

2.1 ± 0.9

0.951

TC, mmol/L

4.8 ± 0.7

4.7 ± 0.7

0.874

4.4 ± 1.1

4.8 ± 0.6

0.363

LDL-c, mmol/L

3.0 ± 0.7

2.9 ± 0.8

0.762

2.9 ± 1.2

3.1 ± 0.8

0.611

HDL-c, mmol/L

1.3 ± 0.4

1.2 ± 0.4

0.481

1.2 ± 0.3

1.5 ± 0.3

0.059

Creatinine, μmol/L

69.5 ± 13.4

77.1 ± 21.6

0.357

66.4 ± 13.5

71.0 ± 14.3

0.480

ACR, mg/g

6.7 ± 0.7

10.5 ± 2.1

0.100

8.7 ± 5.5

7.3 ± 1.2

0.494

eGFR, mL/min †

92.5 ± 20.7

75.2 ± 19.2

0.078

74.8 ± 6.7

78.6 ± 6.2

0.686

BCVA, logMAR

0.3 ± 0.1

0.2 ± 0.1

0.007

0.2 ± 0.1

0.2 ± 0.2

0.883

AL, mm

23.7 ± 0.6

23.5 ± 1.5

0.594

23.4 ± 1.1

23.3 ± 0.7

0.803

IOP, mmHg

16.2 ± 2.5

15.7 ± 2.7

0.665

14.1 ± 3.1

15.2 ± 2.3

0.397

T2DM duration, year

22.0 ± 0.7

2.2 ± 0.4

 < 0.001

2.4 ± 0.4

2.3 ± 0.5

0.930

Insulin, %

3 (30%)

1 (10%)

0.303

1 (10%)

1 (10%)

1.000

Oral antihyperglycemic agents, %

10 (100%)

10 (100%)

1.000

10 (100%)

10 (100%)

1.000